Outcomes of First-Line Anti-PD-L1 Blockades Combined with Brain Radiotherapy (BRT) for Extensive-Stage SmallCell Lung Cancer (ES-SCLC) with Brain Metastases (BM)

被引：0
|
作者：
Tian, Y. [1 ]
Ma, J. [2 ]
Zhu, H. [3 ]
Yu, J. [3 ]
机构：
[1] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, Dept Radiat Oncol, Shandong Canc Hosp & Inst, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2804
引用
收藏
页码：E360 / E360
页数：1
相关论文
共 50 条
  • [1] Outcomes of anti-PD-L1 blockades plus etoposide and platinum (EP) as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) with brain metastasis (BM).
    Tian, Yaru
    Ma, Ji
    Zhu, Hui
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis
    Ji Ma
    Yaru Tian
    Shaoyu Hao
    Liangjie Zheng
    Weibo Hu
    Xiaoyang Zhai
    Dongfang Meng
    Hui Zhu
    Journal of Neuro-Oncology, 2022, 159 : 685 - 693
  • [3] Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis
    Ma, Ji
    Tian, Yaru
    Hao, Shaoyu
    Zheng, Liangjie
    Hu, Weibo
    Zhai, Xiaoyang
    Meng, Dongfang
    Zhu, Hui
    JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (03) : 685 - 693
  • [4] Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC
    Lu, S.
    Guo, X.
    Li, Y.
    Liu, H.
    Zhang, Y.
    Zhu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S379 - S380
  • [5] Real-World Outcomes of Platinum-immunotherapy as First-Line (1L) Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Ganti, A. K.
    Prince, T.
    Back, S.
    Chansakul, A.
    Boccuti, A.
    Rengarajan, B.
    Chakrabarti, D.
    Li, W.
    Fan, L.
    Cao, Y.
    D'Agostino, R., Jr.
    Fan, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S664 - S665
  • [6] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [7] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes
    Schulz, C.
    Chen, Y.
    Paz-Ares, L. G.
    Dvorkin, M.
    Trukhin, D.
    Reinmuth, N.
    Garassino, M. C.
    Statsenko, G.
    Voitko, O.
    Hochmair, M. J.
    Ozguroglu, M.
    Verderame, F.
    Havel, L.
    Losonczy, G.
    Conev, N.
    Hotta, K.
    Ji, J. H.
    Broadhurst, H.
    Byrne, N.
    Thiyagarajah, P.
    Goldman, J. W.
    Alt, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 144 - 145
  • [8] Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
    Nadler, Eric S.
    Vasudevan, Anupama
    Davies, Kalatu
    Wang, Yunfei
    Johnson, Ann
    Ogale, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
    Chen, Yuanbin
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Trukhin, Dmytro
    Reinmuth, Niels
    Chiara Garassino, Marina
    Statsenko, Galina
    Voitko, Oleksandr
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Verderame, Francesco
    Havel, Libor
    Losonczy, Gyorgy
    Conev, Nikolay
    Hotta, Katsuyuki
    Ji, Jun Ho
    Broadhurst, Helen
    Byrne, Natalie
    Thiyagarajah, Piruntha
    Wade Goldman, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
    Daniel, D.
    Kuchava, V.
    Bondarenko, I.
    Ivashchuk, O.
    Spigel, D.
    Dasgupta, A.
    Reddy, S.
    Melkadze, T.
    Jaal, J.
    Kudaba, I.
    Hart, L.
    Matitashvili, A.
    Koynov, K. D.
    Yang, Z.
    Wolfe, S. G.
    Malik, R.
    Morris, S. R.
    Antal, J. M.
    Goldschmidt, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
12345